Trusted Resources: News & Events
Latest announcements and gatherings
Voxelotor for Sickle Cell Disease Wins FDA Nod for Patients as Young as 4
Voxelotor has a novel mechanism of action. The first-in-class therapy regulates the affinity of hemoglobin for oxygen, resulting in a decrease in the concentration of deoxygenated sickle hemoglobin (HbS), which forms polymers. It’s hypothesized that because oxygenated HbS cannot polymerize, modifying HbS to increase the proportion of oxygenated to deoxygenated HbS in red blood cells would alter disease severity.
The FDA Friday approved the wider use of voxelotor (Oxbryta) in patients with sickle cell disease (SCD) as young as 4 years of age. In 2019, the oral polymerization inhibitor was approved by the FDA for adults and pediatric patients with SCD 12 years of age and older.
+myBinderRelated Content
-
Tammuella (Tami) Singleton, MDDr. Singleton serves as a pediatric hema...
-
Piracetam for reducing the incidence of painful sickle cell disease crisesBACKGROUND: Sickle cell disease is one ...
-
Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell diseaseSickle cell disease (SCD) is complicated...
-
Jerlym S. Porter, PhD, MPHJerlym S. Porter is an Associate Member ...
-
Sickle cell trait may not increase the risk of deathPeople who carry a gene for sickle cell ...
-
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
-
FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.